List of Excipients in Branded Drug ENABLEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ENABLEX	darifenacin	0430-0170	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Allergan Inc	ENABLEX	darifenacin	0430-0170	HYPROMELLOSES
Allergan Inc	ENABLEX	darifenacin	0430-0170	MAGNESIUM STEARATE
Allergan Inc	ENABLEX	darifenacin	0430-0170	POLYETHYLENE GLYCOL 200
Allergan Inc	ENABLEX	darifenacin	0430-0170	TALC
Allergan Inc	ENABLEX	darifenacin	0430-0170	TITANIUM DIOXIDE
Physicians Total Care Inc	ENABLEX	darifenacin	54868-5704	ANHYDROUS DIBASIC CALCIUM PHOSPHATE

Enablex Excipient Strategy and Commercial Opportunities for Darifenacin Extended-Release Tablets

Last updated: August 24, 2026

Enablex is the branded extended-release formulation of darifenacin hydrobromide, an antimuscarinic indicated for overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Its commercial value now lies primarily in generic formulation development, differentiated modified-release products, regional licensing, and excipient-led improvements in manufacturability and tolerability. Core U.S. composition-of-matter and formulation barriers have largely matured, while formulation execution remains the main technical risk for competitors.

What is Enablex and which excipients does it use?

Enablex contains darifenacin hydrobromide in 7.5 mg and 15 mg extended-release tablets. The formulation uses a hydrophilic matrix approach designed to release darifenacin over an extended period.

The U.S. prescribing information identifies the following inactive ingredients:

Excipient	Likely formulation role
Hypromellose	Hydrophilic matrix former and release-rate controller
Calcium hydrogen phosphate	Diluent and tablet-body former
Magnesium stearate	Lubricant
Polyethylene glycol	Film-coating or plasticization function
Talc	Anti-adherent and coating aid
Titanium dioxide	Opacifier and colorant

The exact quantitative composition and manufacturing parameters are not disclosed in the public prescribing information. Those parameters can materially affect dissolution, tablet hardness, moisture sensitivity, and bioequivalence.

Enablex is a once-daily oral dosage form. The formulation must maintain controlled release despite variability in gastrointestinal fluid composition, transit time, food intake, and tablet mechanical properties. Darifenacin is metabolized primarily through CYP2D6 and CYP3A4, making drug-drug interaction management a larger clinical consideration than excipient tolerability in most patients.[1]

What excipient strategy is appropriate for an Enablex generic?

A generic developer should treat the product as a release-critical matrix tablet rather than as a conventional immediate-release oral solid. The highest-value excipient decisions concern matrix robustness, processability, and dissolution reproducibility.

Matrix former selection

Hypromellose is the central excipient in the reference formulation. A generic developer can use hypromellose directly or evaluate other hydrophilic polymers, but substitution creates a meaningful formulation risk.

Critical variables include:

• Polymer viscosity grade
• Particle-size distribution
• Degree of substitution
• Polymer loading
• Compression force
• Granulation method
• Tablet porosity
• Exposure to water and humidity

Higher-viscosity hypromellose grades generally increase gel strength and can slow drug release. Lower-viscosity grades may improve processing but create a faster or less stable release profile. The objective is not simply to match the labeled excipient list. The objective is to reproduce the reference product's in vitro release behavior across the full shelf-life period.

Polyethylene oxide, hydroxypropyl cellulose, or polymer blends may offer alternative release control, but these approaches increase regulatory and bioequivalence risk. A formulation that uses a different matrix system may qualify as a pharmaceutically equivalent product only if it satisfies the applicable regulatory requirements and demonstrates comparable performance.

Diluent strategy

Calcium hydrogen phosphate provides bulk and contributes to tablet strength. It has relatively low hygroscopicity compared with many soluble fillers, which can support stability. Its brittle deformation characteristics can also help produce mechanically robust tablets.

Potential alternatives include microcrystalline cellulose, lactose, mannitol, or combinations of these materials. Each alternative changes:

• Compression behavior
• Tablet porosity
• Water penetration
• Matrix hydration
• Drug release
• Content uniformity
• Scale-up performance

Microcrystalline cellulose may improve compactibility but can alter water uptake and gel formation. Lactose can provide favorable tableting properties but may introduce greater moisture or chemical compatibility considerations depending on the formulation. A calcium phosphate-based platform is therefore commercially attractive for developers seeking closer alignment with the reference product.

Lubricant control

Magnesium stearate is necessary for ejection and tooling protection, but excessive lubrication can reduce tablet hardness and slow wetting. Over-lubrication can also produce batch-to-batch dissolution variability.

A robust control strategy should define:

• Lubrication time
• Blender speed
• Lubricant concentration
• Granule surface area
• Blend uniformity
• Ejection force
• Dissolution impact

Sodium stearyl fumarate may be considered where magnesium stearate causes processing or dissolution problems. However, changing the lubricant can affect tablet behavior and should not be treated as a low-risk substitution.

Film-coating system

Polyethylene glycol, talc, and titanium dioxide are consistent with a conventional protective film coat. The coating can improve swallowability, identification, handling, and protection from environmental exposure.

The coating is unlikely to control the primary release mechanism if the drug is embedded in a hydrophilic matrix. It can still affect:

• Initial wetting
• Tablet surface integrity
• Moisture ingress
• Appearance and product differentiation
• Mechanical protection during packaging and distribution

A pigmented, moisture-resistant coating could support regional commercialization, particularly in hot and humid markets. The developer must ensure that the coating does not create an unintended lag time or alter dissolution during scale-up.

What formulation attributes create commercial opportunity?

The most defensible opportunities are based on manufacturing efficiency, supply resilience, and patient-use improvements rather than unclaimed therapeutic positioning.

Excipient supply-chain substitution

A developer can create value by qualifying multiple sources for hypromellose, calcium hydrogen phosphate, magnesium stearate, and film-coating components. This reduces dependence on a single supplier and lowers exposure to:

• Excipient shortages
• Regional import restrictions
• Commodity-price volatility
• Supplier manufacturing changes
• Long lead times for specialty polymer grades

The main constraint is that polymer grade equivalence cannot be assumed from compendial compliance alone. Hypromellose from two suppliers may meet the same pharmacopeial monograph while producing different hydration and dissolution behavior.

Direct-compression manufacturing

A direct-compression process could reduce equipment requirements, solvent exposure, cycle time, and operating cost. The commercial benefit depends on achieving acceptable content uniformity and tablet robustness at the relatively low darifenacin drug load.

A direct-compression design should focus on:

• Drug-excipient segregation
• Uniform distribution of low-dose active ingredient
• Powder flow
• Lubrication sensitivity
• Weight variation
• Compression-force control

If direct compression cannot reproduce the reference dissolution profile, a dry-granulation or wet-granulation route may provide better process control. The cheapest process is not necessarily the lowest-cost commercial process if it generates more dissolution failures or requires extensive in-process testing.

Smaller tablets and improved swallowability

Enablex is a once-daily product for a population that may include older adults and patients taking multiple medicines. A smaller tablet, smoother film coat, or improved tablet shape could provide a commercial point of differentiation, subject to regulatory restrictions and the absence of unsupported adherence claims.

Size reduction must preserve:

• Dose uniformity
• Matrix integrity
• Extended-release performance
• Mechanical strength
• Stability
• Labeling compliance

A smaller tablet may require higher-density excipients, stronger compression, or a different matrix concentration. These changes can affect drug release and must be evaluated as a complete formulation system.

Regional formulation localization

Markets with high humidity and temperature variability create opportunities for packaging and coating optimization. Options include:

• High-barrier blister packaging
• Desiccant-containing bottles
• Moisture-resistant film coatings
• Lower-permeability packaging materials
• Regional stability programs

The value is greatest where distribution conditions are difficult and where a generic manufacturer can reduce product loss or extend distribution reach without changing the active formulation.

What generic entry risks exist for Enablex?

Enablex has no biosimilar risk because darifenacin is a chemically synthesized small molecule. The relevant competitive pathway is an abbreviated new drug application, or equivalent national generic pathway, for darifenacin extended-release tablets.

The principal generic risks are technical:

1. Failure to match the reference dissolution profile.
2. Inability to demonstrate bioequivalence for the extended-release product.
3. Variability caused by polymer grade or lubricant changes.
4. Inadequate stability under high-temperature and high-humidity conditions.
5. Scale-up changes that alter tablet porosity or matrix hydration.
6. Difficulty achieving consistent release at both 7.5 mg and 15 mg strengths.
7. Regulatory scrutiny of a formulation that departs materially from the reference product.

For an extended-release product, a formulation can pass early development testing and still fail during scale-up. The commercial program should lock critical material attributes and critical process parameters before pivotal bioequivalence manufacture.

What is the FDA regulatory status of Enablex?

Enablex was approved by the FDA for overactive bladder in 2004 under NDA 021430. The product was developed and marketed by Novartis. The U.S. product is associated with darifenacin hydrobromide extended-release tablets in 7.5 mg and 15 mg strengths.[1][2]

Darifenacin extended-release products have also entered generic markets. FDA approval of generic products does not eliminate formulation competition. It shifts competition toward:

• Wholesale acquisition cost
• Medicaid and payer contracting
• Pharmacy-channel access
• Supply reliability
• Authorized or branded-generic positioning
• Manufacturing cost

The FDA Orange Book remains the primary source for current approved products, therapeutic-equivalence codes, patent listings, and exclusivity information. Product marketing status can change independently from the original NDA approval record, so commercial planning should distinguish between historical approval, current listing, and active distribution.[2]

What patents protect Enablex and when does exclusivity end?

The original darifenacin compound and extended-release formulation patents are mature relative to the product's 2004 U.S. approval. Generic competition has therefore been possible for years, subject to the patent and regulatory records applicable at the time of each ANDA filing.

The relevant IP categories include:

IP category	Commercial relevance
Darifenacin compound patents	Historically protected the active pharmaceutical ingredient
Extended-release formulation patents	Could cover matrix composition, release profile, or dosage form
Manufacturing patents	May cover granulation, compression, coating, or process controls
Method-of-use patents	May address treatment of overactive bladder or dosing conditions
Trademark rights	Protect the Enablex name but do not block generic active-ingredient products

Current patent status should be checked in the FDA Orange Book and USPTO records before any launch or licensing decision. A patent that has expired, been delisted, or become legally ineffective cannot be treated as a current market barrier. Conversely, a formulation or method patent may still create litigation exposure even after compound protection has expired.

The commercial conclusion is clear: Enablex is primarily a formulation and market-access opportunity, not a late-stage compound-exclusivity opportunity.

Are there Paragraph IV challenges and Enablex patent litigation?

Paragraph IV risk is relevant only where an applicant challenges a listed patent as invalid, unenforceable, or not infringed. Publicly reported litigation history for older products can be fragmented across FDA records, district-court dockets, and settlement documents.

For Enablex, the highest-value legal review should focus on:

• Orange Book-listed patents associated with NDA 021430
• ANDA applicants and notice letters
• District-court complaints under Hatch-Waxman
• Preliminary injunctions and stays
• Litigation settlements
• Launch dates tied to patent expiry or settlement terms
• Any authorized-generic arrangements

A generic launch plan should not rely solely on the absence of a recent high-profile lawsuit. Older patent disputes may have been resolved through settlements, license agreements, or commercial arrangements that are not obvious from the product label.

Which excipient-based commercial models are available?

Low-cost generic platform

The simplest opportunity is a pharmaceutically equivalent extended-release tablet using a conventional hypromellose matrix and standard film coating. The advantage is regulatory familiarity and lower development complexity.

This model competes on:

• Cost of goods
• Supply reliability
• Approval timing
• Payer access
• Manufacturing scale

Premium generic with supply reliability

A manufacturer can position the product around consistent availability, dual-source excipient qualification, and resilient packaging. This is useful in markets where generic shortages or supplier changes have affected antimuscarinic products.

Regional licensing

A company with approved manufacturing capacity but limited commercial reach could license darifenacin extended-release tablets to regional partners. The asset is more suitable for a portfolio deal than a standalone premium transaction because the active ingredient is mature and competition is established.

Reformulated once-daily antimuscarinic

A new formulation could pursue improved tablet size, lower process variability, or alternative release control. The regulatory route and patent value would depend on the degree of technical differentiation and the jurisdiction. A new excipient combination alone may not produce enforceable exclusivity.

Combination-product opportunity

Darifenacin could be evaluated in a broader overactive-bladder portfolio involving other oral agents or non-pharmacologic adherence tools. Fixed-dose combinations would face clinical, regulatory, and intellectual-property hurdles and should not be treated as a near-term excipient opportunity.

How does Enablex compare with competing overactive-bladder drugs?

Product	Active ingredient	Dosage form	Main formulation issue	Competitive position
Enablex	Darifenacin hydrobromide	Extended-release tablet	Hydrophilic matrix control	Mature antimuscarinic
Detrol LA	Tolterodine tartrate	Extended-release capsule	Multiparticulate or capsule release system	Mature generic market
Vesicare	Solifenacin succinate	Tablet	Immediate-release oral tablet	Strong brand recognition and generic competition
Ditropan XL	Oxybutynin chloride	Extended-release tablet	Controlled-release matrix or osmotic technology depending on product	Older, low-cost comparator
Myrbetriq	Mirabegron	Extended-release tablet	Controlled-release oral tablet	Beta-3 agonist competitor, not an antimuscarinic

Enablex can be differentiated through formulation quality, tolerability positioning consistent with the approved label, and reliable supply. It is unlikely to command a major premium solely because of its excipient profile.

What manufacturing and IP barriers matter most?

The key manufacturing barrier is reproducible release control at commercial scale. The key IP barrier is determining whether any surviving formulation, process, or method-of-use rights constrain a specific product design.

A commercial development program should establish:

• Excipient specifications tighter than minimum compendial standards where needed
• Two qualified sources for critical polymer grades
• Comparative dissolution across pH conditions
• Alcohol-dose-dumping evaluation where applicable
• Robustness testing after accelerated stability
• Scale-up comparability
• Packaging compatibility
• Tablet mechanical-strength limits
• Separate control strategies for 7.5 mg and 15 mg strengths

The most valuable technical package is a formulation that is easy to manufacture, stable in regional climates, and sufficiently close to the reference product to reduce bioequivalence risk.

What is the revenue exposure for Enablex?

Public revenue exposure depends on geography, active product status, generic penetration, pricing, and whether sales are attributed to the originator or generic manufacturers. The branded product's commercial peak occurred before broad generic erosion. Current opportunity is more likely to arise from volume, portfolio fit, and manufacturing efficiency than from premium branded pricing.

A prospective manufacturer should model:

• Generic price erosion
• Number of approved competitors
• Pharmacy substitution rates
• Payer reimbursement
• API cost
• Excipient cost
• Batch size
• Annual tablet volume
• Regulatory maintenance expense
• Launch timing by jurisdiction

The revenue case is strongest for a company that already manufactures oral modified-release products and can add darifenacin without building a dedicated platform.

Key Takeaways

• Enablex is darifenacin hydrobromide in 7.5 mg and 15 mg extended-release tablets.
• Hypromellose is the principal release-controlling excipient; calcium hydrogen phosphate, magnesium stearate, polyethylene glycol, talc, and titanium dioxide support tablet manufacture and coating.
• The principal technical risk is reproducing the reference dissolution profile after scale-up and stability testing.
• Generic and regional licensing opportunities are more attractive than new-compound exclusivity opportunities.
• Dual-source qualification for hypromellose and other critical excipients can create supply and cost advantages.
• Smaller tablets, moisture-resistant packaging, and improved manufacturability are realistic differentiation paths.
• Enablex has no biosimilar risk because darifenacin is a small-molecule drug.
• Current patent, Orange Book, litigation, and exclusivity status must be evaluated against the specific jurisdiction and proposed product design.

FAQs

Can hypromellose be replaced in a darifenacin extended-release tablet?

Yes, but replacement can materially change hydration, gel strength, dissolution, and bioequivalence risk. A different polymer should be supported by comparative dissolution and stability data.

Is calcium hydrogen phosphate essential to the Enablex formulation?

No. It is an important reference-product excipient, but alternatives may be possible. Substitution can change compression, porosity, water penetration, and drug release.

Does a different excipient composition create new patent protection?

Not automatically. A novel composition may support patent protection only if it satisfies applicable novelty, inventive-step, enablement, and written-description standards. Regulatory approval does not itself create patent rights.

Is darifenacin suitable for an authorized-generic strategy?

Potentially. The opportunity depends on the current NDA holder's commercial rights, active distribution, manufacturing economics, and any licensing or settlement arrangements.

What is the most important quality test for an Enablex generic?

Comparative extended-release dissolution is the central development test, but it must be evaluated with content uniformity, mechanical strength, stability, and in vivo bioequivalence.

References

1. U.S. Food and Drug Administration. (2004). Enablex (darifenacin hydrobromide) extended-release tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Enablex, NDA 021430. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2012). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

5. U.S. Food and Drug Administration. (2013). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.